Parametric Portfolio Associates LLC grew its stake in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 4.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 646,042 shares of the medical equipment provider’s stock after buying an additional 25,859 shares during the quarter. Parametric Portfolio Associates LLC’s holdings in Zimmer Biomet were worth $76,065,000 at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in ZBH. Geode Capital Management LLC grew its stake in shares of Zimmer Biomet by 8.4% during the fourth quarter. Geode Capital Management LLC now owns 2,641,717 shares of the medical equipment provider’s stock valued at $273,516,000 after buying an additional 205,532 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Zimmer Biomet by 34.6% during the first quarter. Janus Henderson Group PLC now owns 72,118 shares of the medical equipment provider’s stock valued at $9,210,000 after buying an additional 18,553 shares during the last quarter. United Bank grew its stake in shares of Zimmer Biomet by 9.9% during the first quarter. United Bank now owns 11,003 shares of the medical equipment provider’s stock valued at $1,405,000 after buying an additional 988 shares during the last quarter. Mn Services Vermogensbeheer B.V. grew its stake in shares of Zimmer Biomet by 1.7% during the first quarter. Mn Services Vermogensbeheer B.V. now owns 35,118 shares of the medical equipment provider’s stock valued at $4,485,000 after buying an additional 600 shares during the last quarter. Finally, Toronto Dominion Bank grew its stake in shares of Zimmer Biomet by 16.6% in the first quarter. Toronto Dominion Bank now owns 141,982 shares of the medical equipment provider’s stock worth $18,126,000 after purchasing an additional 20,247 shares during the last quarter. 89.39% of the stock is currently owned by hedge funds and other institutional investors.
In other Zimmer Biomet news, VP Chad F. Phipps sold 32,800 shares of Zimmer Biomet stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $140.00, for a total transaction of $4,592,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Didier Deltort sold 360 shares of Zimmer Biomet stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $139.25, for a total value of $50,130.00. Following the sale, the insider now directly owns 1,194 shares in the company, valued at $166,264.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 40,391 shares of company stock worth $5,642,274. Insiders own 0.72% of the company’s stock.
Several research firms recently issued reports on ZBH. Morgan Stanley raised their target price on Zimmer Biomet from $143.00 to $150.00 and gave the stock an “overweight” rating in a research note on Monday, July 29th. Citigroup raised their target price on Zimmer Biomet from $146.00 to $158.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Credit Suisse Group raised their target price on Zimmer Biomet from $101.00 to $120.00 and gave the stock an “underperform” rating in a research note on Monday, July 29th. Sanford C. Bernstein raised Zimmer Biomet from an “underperform” rating to a “market perform” rating and set a $121.71 target price on the stock in a research note on Tuesday, June 11th. Finally, Argus raised Zimmer Biomet from a “hold” rating to a “buy” rating and set a $160.00 target price on the stock in a research note on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. Zimmer Biomet presently has an average rating of “Buy” and an average price target of $142.26.
Zimmer Biomet stock traded down $3.56 during trading hours on Friday, hitting $139.05. 471,657 shares of the stock traded hands, compared to its average volume of 905,914. The firm’s 50-day moving average price is $136.59 and its two-hundred day moving average price is $125.34. The company has a current ratio of 1.19, a quick ratio of 0.56 and a debt-to-equity ratio of 0.58. The company has a market cap of $28.44 billion, a PE ratio of 18.20, a PEG ratio of 2.48 and a beta of 1.15. Zimmer Biomet Holdings Inc has a one year low of $96.99 and a one year high of $143.00.
Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Friday, July 26th. The medical equipment provider reported $1.93 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.91 by $0.02. The business had revenue of $1.99 billion for the quarter, compared to analysts’ expectations of $1.98 billion. Zimmer Biomet had a positive return on equity of 13.40% and a negative net margin of 4.56%. The business’s revenue was down .9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.92 EPS. On average, sell-side analysts expect that Zimmer Biomet Holdings Inc will post 7.82 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Friday, September 27th. This represents a $0.96 annualized dividend and a yield of 0.69%. Zimmer Biomet’s payout ratio is 12.57%.
Zimmer Biomet Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Further Reading: What does a bar chart display?
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.